An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Ascletis, a biotech company, has filed two IND applications with the U.S. Food and Drug Administration. An IND (investigational new drug) application is the paperwork a company submits to ask permission to start clinical trials in people. The filings are for two once-monthly injectable drugs aimed at treating obesity. The main drug, called ASC36, is described as a peptide amylin receptor agonist. In plain terms, a peptide is a small protein-like molecule. "Amylin" is a natural hormone that works with insulin and helps control appetite and how quickly the stomach empties. An "agonist" just means the drug mimics amylin’s action at its receptor. The second product, ASC36_35 FDC, is a co-formulation — meaning it mixes ASC36 with another peptide that acts on GLP-1 and GIP receptors. GLP-1 and GIP are other gut hormones involved in appetite, blood sugar, and digestion. Combining mechanisms is a strategy companies use to try to boost weight-loss effects. The announcement is about regulatory filings, not results from large human trials. An IND lets the company begin clinical studies in people; it does not prove the drugs work or are safe yet. The snippet doesn’t provide human data, trial sizes, or efficacy numbers. So at this stage, all we know is that Ascletis plans to test a single monthly injectable amylin mimic alone, and a once-monthly combo of that amylin mimic plus a GLP-1/GIP-targeting peptide, in clinical studies after getting FDA clearance to proceed. Why this matters is practical: obesity is a major health issue and current drugs like semaglutide (sold as Ozempic or Wegovy) are injections taken weekly that have shown substantial weight loss for many people. A once-monthly option could be more convenient for patients who dislike frequent injections. Also, drugs that target multiple appetite-related hormones at once have, in several recent cases, produced larger weight-loss effects than single-hormone approaches. So if these candidates prove safe and effective in trials, they could become another tool for treating obesity. Important caveats: these are early steps. IND submission is administrative — it means trials may start, not that the drugs are proven safe or effective. Peptide drugs can cause side effects like nausea, vomiting, or low blood sugar, and combining mechanisms can increase both benefits and risks. We don’t know dosing, study design, patient populations, or timelines from this announcement. And FDA clearance to start trials is not the same as eventual approval for use. People should not assume these products are available or superior to existing treatments until trial results are published. Bottom line: Ascletis plans to test a monthly amylin-mimic injection and a monthly combo that adds GLP-1/GIP activity for obesity, but real-world benefit and safety will depend on the results of future clinical trials.
Source: PR Newswire